A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance - Summary - MDSpire
Clinical Guidelines

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

  • By

  • Kimberly Noonan, DNP, ANP-BC, AOCN, FAAN

  • Kevin Brigle, PhD, ANP

  • Charise Gleason, MSN, NP-C, AOCNP

  • Carrie Bellerive, BS, RN, BMTCN

  • Mary Steinbach, DNP, APRN

  • Deborah Doss, RN, OCN

  • March 4, 2026

  • 17 min

Share

A 54-year-old African American woman, Ms. Jones, with a newly diagnosed immunoglobulin A lambda monoclonal gammopathy of undetermined significance (MGUS), presents with worsening neuropathy. With a history of type 2 diabetes and hypertension, she undergoes further workup which shows intermediate-risk MGUS and a 37% progression risk to multiple myeloma over 20 years. After thorough discussion about treatment options, Ms. Jones opts for monitoring her condition instead of immediate biopsy. Key findings on MGUS include its asymptomatic nature, risk stratification, and necessity for ongoing observation.

Original Source(s)

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

  • by Kimberly Noonan, DNP, ANP-BC, AOCN, FAAN, Kevin Brigle, PhD, ANP, Charise Gleason, MSN, NP-C, AOCNP, Carrie Bellerive, BS, RN, BMTCN, Mary Steinbach, DNP, APRN, Deborah Doss, RN, OCN

  • March 4, 2026

Related Content

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies

  • May 13, 2026

  • 3 min
Complex Hematologic Malignancy Management in a TP53-Mutated Patient: Balancing Disease Control and Quality of Life

Cytogenetic and molecular testing revealed a complex karyotype and a TP53 mutation, placing her disease in an adverse-risk category.

  • by

  • April 27, 2026

  • 5 min
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs

Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published ...